Risk factors for febrile neutropenia admissions associated with chemotherapy

• Autores: Manuel Koninckx Cañada, J.L. Marco Garbayo, Isabel Pérez Castelló, Mª Teresa Faus Soler, E. Peiró Barber
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 18, Nº. 4, 2016, págs. 223-231
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective: To analyze Hospital Admissions (HA) for Febrile Neutropenia (FN) secondary to Chemotherapy Treatment (CT).

    Method: Retrospective observational study, carried out in the framework of integral risk-management plan of drugs and proactive pharmacovigilance, of FN admissions secondary to CT treatment during 2014. Cases were identified after review of the ICD-9 codes related to FN of hospital discharge reports. Various biometric, clinical and pharmacotherapeutic variables of each patient were registered. CT is classified based on the FN risk according to ASCO, EORTC and NCCN guidelines.

    Results: The prevalence of HA for FN was 7.4% (25 cases). The average length of stay was 7 ±4 days. The average mortality rate was 8%. Two cases (8%) received CT with high risk of FN, fifteen (60%) with medium risk and eight (32%) with low risk. The most important risk factors for increased FN incidence were: advanced stage of disease (68% of patients), age ≥65 years (60%) and pre-CT hemoglobin level of <12 g/dl. Prophylactic G-CSF is used in 38% of cases with overall FN risk of ≥20%. 57% who continued with CT had delays and/or dose reductions.

    Conclusion: The availability of an integral risk-management plan of drugs has allowed to gauge the situation of FN in our close health system, describing an underutilization of prophylactic G-CSF